

Nanostics and Protean BioDiagnostics Announce American Medical Association has Granted a PLA Code for ClarityDX Prostate.

- ClarityDX Prostate is a validated blood-based diagnostic tool that uses AI-powered learning to help inform patients of their risk for aggressive prostate cancer.
- Florida-based Protean BioDiagnostics offers ClarityDX Prostate to healthcare providers and their patients suspected of having aggressive prostate cancer.

EDMONTON, Alberta – ORLANDO, Florida – February 12 – [Nanostics Inc.](#), a precision health company developing diagnostic tests with its ClarityDX platform technology, and [Protean BioDiagnostics Inc.](#) (Protean) announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for ClarityDX Prostate. ClarityDX Prostate accurately predicts aggressive prostate cancer before a prostate biopsy. The new code 0550U, will become effective April 1, 2025, and is specific to ClarityDX Prostate.

"We are thrilled to receive a unique CPT PLA code from the AMA for ClarityDX Prostate," said Dr. John Lewis, CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta. "This is a key milestone towards ensuring all patients have access to ClarityDX Prostate to help make more informed decisions about whether to do a prostate biopsy."

"This is wonderful news for men and their families worldwide, said Dr. Anthony Magliocco, MD, Founder and CEO of Protean BioDiagnostics. "With this new code, access to ClarityDX Prostate will broaden and have positive life and health systems resources-saving effects. Now, men the world over with their healthcare provider can make faster, accurate decisions and assist greatly in mitigating the risks of prostate cancer".

In North America, about 1 in 8 men will be diagnosed with prostate cancer and 1 in 44 men will die of prostate cancer, making it the second-leading cause of cancer death in American men. Some prostate cancers are low risk because they grow and spread slowly, while others are aggressive cancers because they grow and spread quickly. When detected early, prostate cancer is one of the most successfully treated types of cancer. When used as an adjunctive test, ClarityDX Prostate helps to identify men with aggressive prostate cancer sooner, leading to better outcomes while also minimizing the negative effects associated with overdiagnosis of the disease.

###

About ClarityDX Prostate and How to Order

ClarityDX Prostate uses biological data, clinical information, and AI-powered learning models to generate a risk score for aggressive prostate cancer, marking a significant advancement in



prostate cancer screening. It provides critical support to men and their healthcare providers in making more informed decisions about whether to proceed with a biopsy following a high prostate-specific antigen (PSA) test result or an abnormal Digital Rectal Exam (DRE).

Order ClarityDX Prostate in the US: <https://www.proteanbiodx.com/cdxprostate#pcdx-order>.
Order ClarityDX Prostate in Canada (except Quebec): <https://www.nanosticsdx.com/claritydx-prostate/#order-test-today>. Order ClarityDX Prostate in Quebec: cdllaboratories.com.

About Protean BioDiagnostics Inc.

[Protean BioDiagnostics Inc.](http://www.proteanbiodx.com) is bringing precision care diagnostics to all patients, everywhere, through its innovative Protean MAPS™ System with integrated Virtual Tumor Boards. In addition, Protean assists world-class pharmaceutical and biotech companies in developing clinical assays and companion diagnostics from its CLIA-certified, CAP-accredited laboratory in Orlando, FL. To learn more visit www.proteanbiodx.com. Questions about CDX Prostate? Call us at: 1 (754) 242 9682 or email us at: info@proteanbiodx.com. Follow Protean on [LinkedIn](#), [Twitter](#) or [YouTube](#).

About Nanostics Inc.

[Nanostics Inc.](http://www.nanosticsdx.com) is a private Canadian company that develops and commercializes novel and noninvasive diagnostic tests. Its core technology, ClarityDX®, uses advanced machine learning algorithms to create a disease risk score that predicts the presence of diseases. ClarityDX is applicable to a wide range of cancers and other diseases. Nanostics' lead product, ClarityDX Prostate®, is a test that improves the accuracy of detecting clinically significant prostate cancer. Read more at: www.nanosticsdx.com. Follow Nanostics on [LinkedIn](#), [YouTube](#), [Facebook](#), and [Instagram](#).

Contacts

Nanostics

For corporate inquiries:

John Lewis, Ph.D.

CEO, Nanostics, Inc.

info@nanosticsdx.com

For media inquiries:

Perrin Beatty, Ph.D.

Communications

+1-800-672-2027

Protean BioDiagnostics

For corporate inquiries:

Anthony Magliocco, MD

President and CEO of Protean

BioDiagnostics

magliocco@proteanbiodx.com

+1 (813) 817-2042

For media inquiries:

Rocky Haag

Director of External Affairs

rocky.haag@proteanbiodx.com

+1 (407) 583-9443